Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safe Stop ipi-nivo
NL-OMON60973Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nivolumab and ipilimumab in melanoma, sponsored by Erasmus MC. Primary endpoint: Ongoing response at 12 months. Started Sep 2024; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON60973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60973.